| 2021 | Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement | 배승진 | Article |
| 2018 | Response to Letter to the Editor on our paper "Evaluation of radioisotopic and non-radioisotopic versions of local lymph node assays for subcategorization of skin sensitizers compliant to UN GHS rev 4" by Ha et al. (Submitted 25 Jun 2017) | 배승진; 임경민 | Letter |
| 2021 | Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea | 배승진 | Article |
| 2019 | Statistical analysis of the reproducibility and predictive capacity of MCTT HCE (TM) eye irritation test, a me-too test method for OECD TG 492 | 배승진; 임경민; 이동환 | Article |
| 2020 | The Burden of Cervical Cancer in Korea: A Population-Based Study | 배승진; 이동환; 손경복 | Article |
| 2021 | The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future | 배승진 | Article |
| 2022 | The Impact of Payment Scheme Changes on Medication Adherence and Persistence of Patients Diagnosed with Depression in Korea | 배승진; 배그린 | Article |
| 2020 | Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? | 배승진 | Article |
| 2019 | Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients | 배승진; 손경복 | Article |
| 2021 | Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology | 배승진; 이동환; 배그린 | Article |
